- Home
- EVOK vs ASBP Comparison
EVOK vs ASBP Comparison
Compare EVOK & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- ASBP
- Stock Information
- Founded
- EVOK 2007
- ASBP 2021
- Country
- EVOK United States
- ASBP United States
- Employees
- EVOK N/A
- ASBP N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- ASBP Health Care
- Exchange
- EVOK Nasdaq
- ASBP Nasdaq
- Market Cap
- EVOK 18.4M
- ASBP 18.9M
- IPO Year
- EVOK 2013
- ASBP N/A
- Fundamental
- Price
- EVOK $10.85
- ASBP $0.10
- Analyst Decision
- EVOK
- ASBP
- Analyst Count
- EVOK 0
- ASBP 0
- Target Price
- EVOK N/A
- ASBP N/A
- AVG Volume (30 Days)
- EVOK 246.8K
- ASBP 65.3M
- Earning Date
- EVOK 11-13-2025
- ASBP 11-14-2025
- Dividend Yield
- EVOK N/A
- ASBP N/A
- EPS Growth
- EVOK N/A
- ASBP N/A
- EPS
- EVOK N/A
- ASBP N/A
- Revenue
- EVOK $14,424,652.00
- ASBP $1,941.00
- Revenue This Year
- EVOK $57.38
- ASBP N/A
- Revenue Next Year
- EVOK $59.57
- ASBP N/A
- P/E Ratio
- EVOK N/A
- ASBP N/A
- Revenue Growth
- EVOK 67.40
- ASBP N/A
- 52 Week Low
- EVOK $1.94
- ASBP $0.09
- 52 Week High
- EVOK $10.86
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- EVOK 84.40
- ASBP 28.25
- Support Level
- EVOK $10.66
- ASBP $0.09
- Resistance Level
- EVOK $10.75
- ASBP $0.10
- Average True Range (ATR)
- EVOK 0.06
- ASBP 0.04
- MACD
- EVOK -0.08
- ASBP -0.00
- Stochastic Oscillator
- EVOK 78.26
- ASBP 5.25
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.